Introduction {#sec3}
============

The fentanyl analog cyclopropylfentanyl, N-phenyl-N-\[1-(2-phenylethyl)piperidin-4-yl\] cyclopropanecarboxamide, is a potent μ-receptor agonist first discovered on the illicit market in June 2017 ([@ref1], [@ref2]). It has been involved in at least 78 deaths in Europe and over a hundred in the United States ([@ref2]).

In general, studies on the toxicology of fentanyl analogs are scarce, and the metabolism has been studied only for a few using human liver microsomes ([@ref5], [@ref6]), human hepatocytes ([@ref5], [@ref7]) and/or authentic specimens ([@ref6], [@ref9]). Metabolite identification is the first step in establishing analytical methods that also target metabolites. Such methods can sometimes increase the window of detection ([@ref12]), and ratios between metabolites and the parent compound can be used to estimate time of intake ([@ref13], [@ref14]). Also, metabolite identification might be relevant in forensic toxicology as some metabolites are active and contribute to drug toxicity ([@ref15]).

A metabolism study incubating cyclopropylfentanyl with multi-donor human hepatocytes was recently published by our research group ([@ref7]). The major metabolite (79%) was found to be the normetabolite, the second most abundant (16%) a metabolite monohydroxylated either on the piperidine ring or the phenethyl moiety. Minor metabolites were mainly generated by modifications on the phenethyl moiety producing a hydroxy metabolite, a piperidine N-oxide, a dihydrodiol, a hydroxy methoxy metabolite and a glucuronide (in order of decreasing abundance). However, for five out of seven identified metabolites the exact structure could not be determined. Not knowing the exact structure of major metabolites is problematic as reference materials needed for assay development are much harder to synthesize.

The aims of the present study were (i) to support the production of reference materials for cyclopropylfentanyl by identifying major urinary metabolites, (ii) to provide the exact structure for those metabolites using reference materials synthesized in-house as well as (iii) to provide a synthesis route for those reference materials.

Experimental {#sec4}
============

Case samples {#sec5}
------------

A total of 13 authentic urine samples were obtained from Swedish autopsy cases where cyclopropylfentanyl was identified in femoral blood.

Chemicals and reagents {#sec6}
----------------------

Cyclopropylfentanyl was obtained from Cayman Chemicals (Ann Arbor, MI, USA). Liquid chromatography--mass spectrometry (LC-MS) grade acetonitrile, water and formic acid used for the LC quadrupole time-of-flight MS (LC-QTOF-MS) were obtained from Fisher Scientific (Gothenburg, Sweden), while the ammonium formate (Fluka) was obtained from Sigma-Aldrich (Stockholm, Sweden). β-glucuronidase/arylsulfatase (Helix promatia, 4.5 U/mL and 14 U/mL, respectively) for urine treatment was purchased from Roche (Mannheim, Germany).

Gradient grade acetonitrile, methanol, formic acid p.a. (98%) and sodium acetate p.a. were purchased from Merck (Darmstadt, Germany). Water was produced in-house with a MilliQ Gradient 10 production unit (Millipore, Billerica, MA). Chemicals used for the synthesis of reference materials are described in the supplemental material.

LC-QTOF-MS analysis {#sec7}
-------------------

LC-QTOF-MS analysis was conducted on an Agilent 1290 Infinity ultra-high-performance LC system coupled to an Agilent 6550 iFunnel QTOF (Agilent Technologies, Kista, Sweden).

A 19-min gradient was used on an Acquity HSS T3 column (150 × 2.1 mm, 1.8 μm, Waters, S) using 0.05% formic acid and 10 m[m]{.smallcaps} ammonium formate in water (A) and 0.05% formic acid in acetonitrile (B) as mobile phases at a flow of 500 μL/min. The gradient started with a hold of 1% B for 0.7 min. The metabolites were separated using a linear gradient to 40% B at 13 min followed by a steeper gradient to 95% B at 15 min, which was held until 18 min to wash the column before immediately returning to 1% B until 19 min to re-equilibrate. Injected was 1 μL of sample.

Mass spectrometric data were obtained in positive electrospray ionization mode using Data Dependent Auto MS/MS (gas temperature 150°C, gas flow 18 L/min, nebulizer 50 psig, sheath gas temperature 375°C, sheath gas flow 11 L/min, fragmentor voltage 380 V, collision energy 3 eV at 0 m/z ramped up by 8 eV per 100 m/z, 5 precursors within 200--800 m/z and \>5000 counts per cycle, scan rate 6 spectra/s for MS and 10 spectra/s for MSMS, scan range 100--950 m/z in MS and 50--950 m/z in MSMS).

Sample preparation {#sec8}
------------------

The 13 urine samples were analyzed by LC-QTOF-MS with and without β-glucuronidase/arylsulfatase treatment to identify potential metabolites.

Sodium acetate buffer (300 μL, 1 [m]{.smallcaps}, pH 5) was added to 100 μL urine sample followed by 10 μL β-glucuronidase/arylsulfatase solution in an injection vial. After gentle mixing, samples were incubated for 2 h at 40°C. Similarly, for the non-treated urine samples 100 μL urine was diluted with 310 μL sodium acetate buffer (1 [m]{.smallcaps}, pH 5) in an injection vial.

Data analysis {#sec9}
-------------

A library of potential metabolite formulae based on mono-, di- and trihydroxylations, carbonylation, carboxylation, methylation, dihydrodiol formation, amide hydrolysis, glucuronidation and N-dealkylation to form norcyclopropylfentanyl, as well as combinations thereof, was compiled.

Samples were searched for metabolites using the library and the Find by formula algorithm of the MassHunter Qualitative Analysis software. Identification was based on presence in urine samples from at least three cases but not in controls, chromatographic peak shape, mass error (less than 5 ppm) and interpretable MS/MS spectra.

Reference material synthesis {#sec10}
----------------------------

Based on preliminary data from urinary analysis and previously published hepatocyte metabolites ([@ref7]), seven potential metabolites were selected for synthesis: four metabolites monohydroxylated on the phenethyl moiety (2, 3, 4 and β-hydroxy), the catechol 3,4-dihydroxyphenethyl and the two different O-methylation products of the catechol.

To produce the metabolites of interest, a general synthetic route was developed ([Figure 1](#f1){ref-type="fig"}). The amine of 4-piperidone was boc-protected using di-*tert*-butyl decarbonate and sodium hydroxide in a solvent mixture comprising water:tetrahydrofuran (1:1) as a first step. The resulting carbamate underwent reductive amination by the addition of aniline, acetic acid and sodium triacetoxyborohydride in dichloromethane to form *tert*-butyl 4-anilinopiperidine-1-carboxylate. In a third step, the free amine was acylated using cyclopropanecarbonyl chloride together with N, N-diisopropylethylamine in dichloromethane to create the normetabolite of cyclopropylfentanyl. This compound was used as a scaffold for the synthesis of seven different potential metabolites of cyclopropylfentanyl. The final steps were N-alkylation using the corresponding bromides with Cs~2~CO~3~ in acetonitrile. The bromides were either purchased or synthesized in-house. One synthesis route was reduction followed by an Appel reaction prior to reaction with the normetabolite. Another route was modification after N-alkylation either by reduction using NaBH~4~ (M11) or by debromination using BBr~3~ under N~2~(g) (M5). Synthesis routes can be found in [Supplementary Material](#sup1){ref-type="supplementary-material"}.

###### 

Metabolite areas in hydrolyzed and non-hydrolyzed samples

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **ID**    **Average RT** ^**a**^ **(min)**   **Metabolite**                          **Formula**\       **Average mass** **error (ppm)**   **Avg**\           **Peak area (x10** ^**3**^ **) hydrolyzed (top) and non-hydrolyzed (bottom) samples**                                                                                                                       
                                                                                       **Mass (exact)**                                      **Conj** ^**b**^                                                                                                                                                                                                               
  --------- ---------------------------------- --------------------------------------- ------------------ ---------------------------------- ------------------ --------------------------------------------------------------------------------------- --------- --------- ---------- ---------- --------- --------- ---------- ---------- --------- ---------- ---------- ---------
  M1        7.81                               Norcyclopropylfentanyl                  C15H20N2O          1.48                               3%                 4111                                                                                    368       348       283        7208       1400      544       410        4895                 414        792        26

                                               244.1576                                                                                      4118               367                                                                                     332       268       7212       1366       547       430       4425                  366       750        25         

  M2        8.19                               Phenethyl dihydrodiol                   C23H30N2O3         −0.74                              54%                1642                                                                                              22        54         1460                 37        41         105                             201        

                                               382.2256                                                                                      753                                                                                                                  25        705                                       31                              88                    

  M3        8.28                               Hydroxyphenethyl glucuronide            C29H36N2O8         −0.77                              N/A                                                                                                                                                                                                                            

                                               540.2472                                                   Phase II                           338                                                                                                                  44        1202                            24        110                             172                   

  M4        8.42                               Hydroxy methoxy-phenethyl glucuronide   C30H38N2O9         −0.95                              N/A                                                                                                                                                                                                                            

                                               570.2577                                                   Phase II                           298                                                                                                                            595                             56                                        60                    

  **M5**    **9.37**                           **3,4-Dihydroxy-phenethyl**             **C23H28N2O3**     **−0.60**                          **92%**            **1845**                                                                                **76**              **46**     **1688**             **33**    **133**    **116**                         **282**    

                                               **380.21**                                                                                    **92**             **60**                                                                                                      **121**                                                                   **37**                

  M6        9.43                               Phenethyl quinone                       C23H26N2O3         1.85                               66%                265                                                                                                                    237                                                                       29         

                                               378.1943                                                                                      90                                                                                                                                                                                                                             

  M7        9.55                               Phenethyl quinone                       C23H26N2O3         −0.53                              40%                95                                                                                                                     141                                                                       26         

                                               378.1943                                                                                      51                                                                                                                             92                                                                                              

  **M8**    **9.99**                           **4-Hydroxyphenethyl**                  **C23H28N2O2**     **−1.07**                          **89%**            **2228**                                                                                **35**    **114**   **208**    **4737**   **66**    **115**   **115**    **717**              **52**     **751**    

                                               **364.2151**                                                                                  **318**                                                                                                    **33**    **34**    **380**               **34**              **80**                          **108**               

  **M9**    **10.28**                          **4-Hydroxy-3-methoxy-phenethyl**       **C24H30N2O3**     **−0.34**                          **91%**            **2062**                                                                                          **76**    **41**     **2525**             **41**    **303**    **83**                          **384**    

                                               **394.2256**                                                                                  **227**                                                                                                                        **160**                                   **20**                          **42**                

  **M10**   **10.54**                          **3-Hydroxy-4-methoxy-phenethyl**       **C24H30N2O3**     **0.06**                                              **63**                                                                                                                 **186**                        **21**     **30**                          **24**     

                                               **394.2256**                                                                                                                                                                                                                                                                                                                 

  **M11**   **10.72**                          **β-Hydroxy-phenethyl**                 **C23H28N2O2**     **0.39**                           **36%**            **139**                                                                                           **57**    **44**     **372**    **93**    **30**               **425**                         **70**     

                                               **364.2151**                                                                                  **117**                                                                                                    **50**    **30**    **176**    **50**     **42**                                    **46**    **48**                

  **P**     **11.72**                          **Cyclopropylfentanyl**                 **C23H28N2O**      **0.01**                           **3%**             **4267**                                                                                **114**   **298**   **704**    **3266**   **420**   **411**   **54**     **2816**   **74**    **418**    **1632**   **199**

                                               **348.2202**                                                                                  **4184**           **107**                                                                                 **286**   **685**   **3190**   **412**    **397**   **54**    **2646**   **79**     **394**   **1585**   **194**    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Metabolites in bold identified using reference material.

^a^RT, Retention time

^b^Avg conj, calculated average conjugation

![General synthesis route for reference materials. (i) Boc~2~O, sodium hydroxide, water:tetrahydrofuran (1:1), rt 72 h; (ii) aniline, acetic acid, Na (OAc)~3~BH, dichloromethane, rt 16 h; (iii) cyclopropanecarbonyl chloride, N, N-diisopropylethylamine, dichloromethane, rt 16 h; (iv) dichloromethane:trifluoroacetic acid (5:1), rt 1 h; (v) corresponding bromide, Cs~2~CO~3~, acetonitrile, 60°C 16 h. R~1~, R~2~ = H, OH; R~3~, R~4~ = H, OH or OH, OMe.](bkz057f1){#f1}

All synthesized potential metabolites including the intermediates were characterized using nuclear magnetic resonance (NMR) spectroscopy and LC-MS. ^1^H- and ^13^C-NMR spectra were recorded on a Varian Mercury 300 MHz instrument (25°C in CDCl~3~). All NMR spectra were calibrated using CDCl~3~ as reference. MS data were obtained by a Waters SQD 2 Mass Detector using a gradient from 22% to 90% acetonitrile in 10 m[m]{.smallcaps} ammonium acetate on an Xbridge C18 column (50 × 4.6 mm, 3.5 μm, Waters). See [Supplementary Material](#sup1){ref-type="supplementary-material"} for details.

Results {#sec11}
=======

Based on the criteria detailed above, 11 metabolites of cyclopropylfentanyl were identified in the urine samples ([Table I](#TB1){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}). Five out of seven synthesized reference materials had corresponding signals in the urine samples; only 2- and 3-hydroxyphenethyl cyclopropylfentanyl lacked matching metabolite peaks.

![Metabolic pathway and extracted ion chromatograms of identified metabolites in case \#1. All peaks from hydrolyzed sample from case \#1 except glucuronide metabolites M3 and M4 that were included from the non-hydrolyzed sample. Metabolites M6, M7, M10 and M11 included as panels with ×10 magnification. Bold metabolites verified by reference materials. \*Other potential structures possible.](bkz057f2){#f2}

Except for cyclopropylfentanyl itself and norcyclopropylfentanyl (M1) all metabolites were conjugated in urine based on area differences between the hydrolyzed and non-hydrolyzed samples (metabolites are liberated from conjugates during the hydrolysis). Especially metabolites M5, M8 and M9 were almost entirely conjugated as shown in [Table I](#TB1){ref-type="table"}.

Major metabolites in the hydrolyzed samples were 4-hydroxyphenethyl cyclopropylfentanyl (M8), 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl (M9) phenethyl dihydrodiol cyclopropylfentanyl (M2) and norcyclopropylfentanyl (M1). Norcyclopropylfentanyl was the most abundant metabolite in the non-hydrolyzed samples. Among the minor metabolites, two potential quinone metabolites (M6 and M7) were identified. Cyclopropylfentanyl was found in all samples, both hydrolyzed and non-hydrolyzed.

Discussion {#sec12}
==========

Metabolite identification of metabolites using reference standards {#sec13}
------------------------------------------------------------------

Five metabolites, 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5), 4-hydroxyphenethyl cyclopropylfentanyl (M8), 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl (M9), 3-hydroxy-4-methoxyphenethyl cyclopropylfentanyl (M10) and β-hydroxyphenethyl cyclopropylfentanyl (M11) were identified by reference materials synthesized in-house. The urinary metabolites were matched to the reference materials by accurate mass, retention time and MS/MS spectra match, as shown in [Figure 3](#f3){ref-type="fig"}.

![Matching MS/MS spectra of urine samples (top) and the synthesized reference materials (bottom). \*m/z 137 and 220 in M8 reference spectra originate from coelution with another reference material.](bkz057f3){#f3}

Metabolite identification of phase I metabolites using MS/MS spectra {#sec14}
--------------------------------------------------------------------

Metabolites lacking a matching reference material were identified based on the MS/MS spectra ([Figure 4](#f4){ref-type="fig"}). Norcyclopropylfentanyl (M1) was mainly identified by accurate mass but also based on fragments m/z 69, 84, 162 and 177, indicating the presence of the cyclopropyl ring and the piperidine moiety (accurate masses are given in [Figure 4](#f4){ref-type="fig"}).

![Representative MS/MS spectra of cyclopropylfentanyl and metabolites not identified using reference material. GLUC indicate glucuronide. \*Other potential structures possible.](bkz057f4){#f4}

Phenethyl dihydrodiol cyclopropylfentanyl (M2) was identified based on the water loss peaks m/z 121 (105 + 16) and 204 (188 + 16) as well as the presence of m/z 69, indicating an unmodified cyclopropyl ring. The exact structure of M2 could not be established; the dihydrodiol can be located in 2,3 or 3,4-position.

Minor metabolites M6 and M7 produced similar MS/MS spectra ([Figure 4](#f4){ref-type="fig"}), consistent with the presence of a quinone structure on the phenethyl moiety that, to our knowledge, has never been reported for any fentanyl analog. M6 and M7 were identified by fragment ions m/z 69 and 228, indicating an unmodified cyclopropyl ring, phenyl and piperidine moiety, as well as m/z 164 indicating a quinone on the phenethyl group. As m/z 132 can potentially be formed from either the phenyl or the phenethyl group, it was of limited value.

Metabolite identification of phase II metabolites {#sec15}
-------------------------------------------------

For the glucuronides M3 and M4, MS/MS spectra similar to the corresponding phase I metabolites M8 and M9 were observed. As 4-hydroxyphenethyl cyclopropylfentanyl (M8) is the most abundant monohydroxylated metabolite, it is reasonable to assume that M3 is the 4-hydroxyphenethyl cyclopropylfentanyl glucuronide. Similarly, M4 is likely to be 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl glucuronide as M9 was observed to be the most abundant of the two isomers (M9 and M10).

Metabolites M2 and M5 were also found to be conjugated ([Table I](#TB1){ref-type="table"}). A glucuronidated dihydrodiol metabolite corresponding to M2 was observed at 7.70 min. Also, either of two glucuronidated dihydroxylated metabolites at 8.21 min and 8.49 min could be the conjugate of 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5). MS/MS spectra of these three peaks supported this conclusion, but as they were not detected in three different cases (only in \#1 and \#5) they were not included.

Cyclopropylfentanyl metabolism {#sec16}
------------------------------

In this study, 11 metabolites of cyclopropylfentanyl were identified in post-mortem urine samples. Two major metabolic pathways were identified: N-dealkylation to form norcyclopropylfentanyl (formed by loss of the phenethyl group) and oxidation of the phenethyl group forming mono- and dihydroxylated metabolites as well as dihydrodiol and quinone metabolites. Oxidized metabolites were further metabolized by methylation and conjugation.

Cyclopropylfentanyl was found in every sample, as shown in [Table I](#TB1){ref-type="table"}. It was the most abundant analyte in 6 out of 13 samples and among the three most abundant analytes in all but one sample (\#8). This may indicate that an acute intake of cyclopropylfentanyl resulted in the rapid death of these subjects and does not necessarily reflect the normal metabolism of cyclopropylfentanyl. The most abundant metabolite was norcyclopropylfentanyl (M1), which was detected in 12/13 samples and was the most abundant analyte in 7/13 hydrolyzed samples. Interestingly, in sample \#8 norcyclopropylfentanyl was more than seven times larger than the peak of cyclopropylfentanyl, perhaps indicating a repeated intake.

Apart from M1, all metabolites were oxidized on the phenethyl group. Major metabolites included 4-hydroxyphenethyl cyclopropylfentanyl (M8), 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5) and 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl (M9). The 4-hydroxy metabolite was previously reported as a major metabolite of acetylfentanyl and fentanyl after hepatocyte incubation ([@ref8]). Interestingly, neither 2- nor 3-hydroxyphenethyl cyclopropylfentanyl was observed in any samples, indicating that the hydroxylation is very selective to the 4-position.

Formation of 4-hydroxy-3-methoxy phenethyl cyclopropylfentanyl (M9) from 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5) is potentially catalyzed by the enzyme catechol-O-methyl transferase (COMT) ([@ref16]). The stereoisomer, 3-hydroxy-4-methoxyphenethyl cyclopropylfentanyl, was also found (M10) but was considerably less abundant. The observed preference of COMT for the 3-position is in line with what has previously been described for the metabolism of other drugs ([@ref16]).

Other minor metabolites included β-hydroxyphenethyl cyclopropylfentanyl (M11) and phenethyl dihydrodiol cyclopropylfentanyl (M2) as well as two phenethyl quinone metabolites (M6 and M7). Quinone metabolites can be formed from dihydrodiols and/or catechols by a number of different oxidative enzymes ([@ref17]). Quinone toxicity through binding to proteins and DNA has also been described ([@ref17]).

Apart from norcyclopropylfentanyl (M1) the metabolites appeared to be 40--91% conjugated in urine based on increased peak area in hydrolyzed samples and further supported by the identification of glucuronide metabolites (M3 and M4). Hydrolysis is recommended for methods aiming to analyze cyclopropylfentanyl metabolites in urine.

Evaluation of the hepatocyte model system {#sec17}
-----------------------------------------

The same LC-QTOF-MS-method was used in this study as in the in the previous metabolism study by Åstrand *et al.* ([@ref7]), which made a direct comparison possible. Of seven detected metabolites after hepatocyte incubation, six were also found in this study (M1, M2, M3, M8, M9 and M11). The last metabolite, an N-oxide, was in fact detected in one hydrolyzed and two non-hydrolyzed urine samples, but as this did not represent three unique cases it was not included in this study.

Despite the overall agreement between the results of the hepatocyte study and this study, a few differences were observed: One of the major metabolites in the urine samples, 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5), was only found at low levels after hepatocyte incubation. In addition, β-hydroxy phenethyl cyclopropylfentanyl (M11) was the most abundant monohydroxylated metabolite after hepatocyte incubations but only a minor metabolite in hydrolyzed urine samples.

The results from the urine samples need to be interpreted with caution as no information about the drug consumed was available, and it is possible that impurities present in the ingested drug is an important contributor to observed metabolite levels. To the best of our knowledge, no studies on drug impurities in seized cyclopropylfentanyl samples have been published.

The correlation between urine samples and hepatocytes is in line with other fentanyl analogs ([@ref10]), but if hepatocytes are used to find analytical targets to analyze urine samples, we recommend that several metabolites to be included and not just the most abundant.

Markers of drug intake {#sec18}
----------------------

A good urinary marker is abundant, unique to the drug and present in most samples. Based on these criteria and the results of this study, cyclopropylfentanyl in itself appears to be a good urinary marker. Norcyclopropylfentanyl (M1) was the most abundant metabolite but is not unique as it could theoretically be produced from other analogs as well. Alternative markers are 4-hydroxyphenethyl cyclopropylfentanyl (M8), 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5) and 4-hydroxy-3-methoxyphenethyl cyclopropylfentanyl (M9) as they are all abundant, unique and present in a majority of the hydrolyzed urine samples. Synthesis routes for these metabolites were provided in the Supplementary Material.

Evaluation of synthesis {#sec19}
-----------------------

In this study, seven metabolites were synthesized as reference materials allowing for the exact identification of five of the metabolites observed in the urine samples. Furthermore, cyclopropylfentanyl was identified by a commercial reference material, and the exact structure of norcyclopropylfentanyl (M1) could be elucidated from accurate mass and MS/MS spectra. Together, the area of these analytes corresponded to 93% of the total analyte area observed in the hydrolyzed urine samples. This study illustrates how a combination of synthesis of potential metabolites and MS/MS spectra interpretation can be successfully applied to elucidate the exact structure of drug metabolites.

Conclusions {#sec20}
===========

Metabolites of cyclopropylfentanyl were identified in 13 post-mortem urine samples. Cyclopropylfentanyl as parent and the metabolite norcyclopropylfentanyl (M1) were the most abundant analytes. Reference materials were synthesized to identify the exact structure of five metabolites; 3,4-dihydroxyphenethyl cyclopropylfentanyl (M5), 4-hydroxyphenethyl cyclopropylfentanyl (M8), 4-hydroxy-3-methoxy-phenethyl cyclopropylfentanyl (M9), 3-hydroxy-4-methoxyphenethyl cyclopropylfentanyl (M10) and β-hydroxyphenethyl cyclopropylfentanyl (M11). Minor metabolites included two quinone metabolites (M6 and M7), not previously reported for fentanyl analogs.

Abundant metabolites M5, M8 and M9 could, together with cyclopropylfentanyl and norcyclopropylfentanyl, serve as urinary markers of cyclopropylfentanyl intake. To facilitate the manufacture of reference materials, synthesis routes were provided.
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